EP1718636A1 - New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation - Google Patents

New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation

Info

Publication number
EP1718636A1
EP1718636A1 EP05711081A EP05711081A EP1718636A1 EP 1718636 A1 EP1718636 A1 EP 1718636A1 EP 05711081 A EP05711081 A EP 05711081A EP 05711081 A EP05711081 A EP 05711081A EP 1718636 A1 EP1718636 A1 EP 1718636A1
Authority
EP
European Patent Office
Prior art keywords
methoxy
benzimidazole
dimethyl
methyl
chiral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05711081A
Other languages
German (de)
French (fr)
Other versions
EP1718636B1 (en
Inventor
Christina Fregler
Sverker Von Unge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1718636A1 publication Critical patent/EP1718636A1/en
Application granted granted Critical
Publication of EP1718636B1 publication Critical patent/EP1718636B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention is directed to new compounds of high optical purity, a process for their preparation and their use as intermediates in the synthesis of the S- or R-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-lH- benzimidazole.
  • a pro-chiral sulphide is oxidised with an oxidising agent in the presence of a chiral titanium complex into the corresponding sulphoxide either as a single enantiomer or in enantiomerically enriched form.
  • WO 98/28294 discloses S-omeprazole in neutral form that is in a solid state.
  • the present invention relates to new crystalline sulphoxides which are stable enough to be directly recrystallised, the preparation of these sulphoxides and their use as intermediates in the synthesis of S- and R- enantiomer of omeprazole.
  • the present invention refers to new highly crystalline sulphoxides in enantiomerically enriched form which are chemically stable enough to be directly crystallised from an oxidation reaction mixture , the preparation of these sulphoxides and their use as intermediates in the synthesis of the S- and R- enantiomer of omeprazole and pharmaceutically acceptable salts thereof.
  • the new synthetic intermediates are defined by formula I either as a single enantiomer or in enantiomerically enriched form:
  • X is a leaving group such as a halogen (F, Cl, Br, I), NO , N + or -OSO 2 R (R is CH 3 , CF 3 , p-toluene, m-chlorobenzene, p-chlorobenzene).
  • halogen F, Cl, Br, I
  • NO NO
  • N + or -OSO 2 R R is CH 3 , CF 3 , p-toluene, m-chlorobenzene, p-chlorobenzene.
  • the leaving group X is chloro or nitro as in the compounds of formula la, lb, Ic and Id:
  • a further aspect of the invention is the preparation of compounds of formula I, which can be used as intermediates in the synthesis of the S- and R- enantiomer of omeprazole and pharmaceutically acceptable salts thereof.
  • the preparation of the compounds of formula I may be carried out as described in EP 0773 940 B 1, and this is also illustrated in Scheme 1 below.
  • X is a leaving group such as a halogen (F, Cl, Br, I), NO 2 , N 2 + or -OSO 2 R (R is CH 3 , CF , p-toluene, m-chlorobenzene, p-chlorobenzene).
  • halogen F, Cl, Br, I
  • NO 2 NO 2
  • N 2 + or -OSO 2 R R is CH 3 , CF , p-toluene, m-chlorobenzene, p-chlorobenzene.
  • a pro-chiral sulphide such as II is oxidised in an organic solvent with an oxidising agent, e.g. cumene hydroperoxide, in the presence of a chiral titanium complex.
  • the titanium complex suitable for catalysing the process of the invention is prepared from a chiral ligand and a titanium(IV) compound such as preferably a titanium(IV)alkoxide, and optionally in the presence of water.
  • the chiral ligand used in the preparation of the titanium complex is for instance a chiral alcohol such as a chiral diol.
  • the oxidation may be performed in the presence of a base, e.g. N,N-diisopropylethylamine.
  • the oxidation is carried out in an organic solvent.
  • the solvent can be chosen with respect to suitable conditions from an industrial point of view as well as environmental aspects. Suitable organic solvents are for instance toluene, ethyl acetate, methyl ethyl ketone, methyl isobutyl ketone, diethyl carbonate, tert.butyl methyl ether, tetrahydrofurane, methylene chloride and the like. From an environmental point of view non-chlorinated solvents are preferred.
  • the oxidation is preferably carried out in an organic solvent at room temperature or just above room temperature, e.g. between 20-40°C. If the reaction time is varied a reaction temperature may be chosen below as well as above the preferred temperatures 20 - 40°C. A suitable temperature range is limited only depending on the decomposition of the compounds, and that the reaction time is dramatically shorter at room temperature than at -20°C since the sulphides of interest are oxidised very slowly at such a low temperature.
  • An oxidising agent suitable for this asymmetric oxidation may be a hydroperoxide, such as for example tert.-butylhydroperoxide or cumene hydroperoxide, preferably the latter.
  • the titanium complex suitable for catalysing the process of the invention is prepared from a chiral ligand and a titanium(IV)compound such as preferably titanium(IV)alkoxide, and optionally in the presence of water.
  • An especially preferred titanium(IN )alkoxide is titanium( ⁇ N)isopropoxide or -propoxide.
  • the amount of the chiral titanium complex is not critical. An amount of less than approximately 0.50 equivalents is preferred and especially preferred amount is 0.05-0.30 equivalents. Even very low amounts of complex, such as for instance 0.04 equivalents may be used in the processes according to the present invention with excellent result.
  • the titanium complex may also be prepared by reacting titanium tetrachloride with a chiral ligand in the presence of a base.
  • the chiral ligand used in the preparation of the titanium complex is preferably a chiral alcohol such as a chiral diol.
  • the diol may be a branched or unbranched alkyl diol, or an aromatic diol.
  • Preferred chiral diols are esters or tartaric acid, especially (+)-diethyl L- tartrate or (-)-diethyl D-tartrate are preferred.
  • the chiral titanium complex may be prepared in the presence of the pro-chiral sulphide or before the pro-chiral sulphide is added to the reaction vessel.
  • the oxidation is carried out in the presence of a base.
  • the base may be an inorganic or an organic base, such as for instance a hydrogen carbonate, an amide or an amine.
  • Amine includes a guanidine or an amidine.
  • Organic bases are preferred and especially suitable bases are amines, preferably triethylamine or N,N- diisopropylethylamine.
  • the amount of base added to the reaction mixture is not critical but should be adjusted with respect to the reaction mixture.
  • the preparation of the chiral titanium complex is preferably performed in the presence of the pro-chiral sulphide.
  • Other essential features in the preparation of the chiral titanium complex is that the preparation of the complex is performed during an elevated temperature and/or a prolonged time.
  • an elevated temperature is meant a temperature above room temperature, such as for instance 30 - 70°C, preferably 40 - 60°C.
  • a prolonged preparation time is a period of time longer than approximately 20 minutes, preferably 1 - 5 hours.
  • a suitable period of time for the preparation step depends on the preparation temperature and of the pro-chiral sulphide, optionally present during the preparation of the chiral titanium complex.
  • Still a further aspect of the invention is the conversion of compounds of formula I into the S- and R- enantiomer of omeprazole and pharmaceutically acceptable salts thereof.
  • Scheme 2 and Scheme 3 below describe synthetic routes for converting compound I into the S- enantiomer of omeprazole. The same routes can be applied to convert compund I into the R-enantiomer of omeprazole provided that the chirality of the chiral titanium complex used in the oxidising reaction step is changed to the opposite of that used for making the corresponding S-enantiomer.
  • the first step is performed as described above.
  • Nucleophilic substitution of the leaving group X with methoxide e.g. sodium methoxide, is thereafter performed prior to or after reduction of the pyridine-N-oxide to pyridine.
  • methoxide e.g. sodium methoxide
  • the compounds of the invention may exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an improved method for the synthesis of the (S)- or (R)-enantiomer of omeprazole, characterized in that 2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-3,5-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole, wherein X is a leaving group, is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallization of the thus obtained sulphoxide results in a compound of enhanced chemical and optical purity, which is subsequently transformed into the (S)- or (R)-enantiomer of omeprazole.

Description

NEW COMPOUNDS USEFUL FOR THE SYNTHESIS OF S- AND R-OMEPRAZOLE AND A PROCESS FOR THEIR PREPARATION
Field of the invention
The present invention is directed to new compounds of high optical purity, a process for their preparation and their use as intermediates in the synthesis of the S- or R-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-lH- benzimidazole.
Background of the invention
The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]- IH-benzimidazole, having the generic name omeprazole, and therapeutically acceptable alkaline salts thereof are described in EP 5129 and EP 124495, respectively. Omeprazole and its alkaline salts are effective gastric acid secretion inhibitors, and are useful as antiulcer agents. The compounds, being sulphoxides, have an asymmetric center in the sulphur atom, i.e. exist as two optical isomers (enantiomers). It has been shown that the magnesium salt of the S-enantiomer of omeprazole has better pharmacokinetic and metabolic properties compared to omeprazole, and this is described in EP 0 652 872 B 1. As a result of this the magnesium salt of the S-enantiomer of omeprazole has an improved therapeutic profile such as a lower degree of interindividual variation. In EP 0773 940 B 1 a process for preparation of the single enantiomers of omeprazole and structurally related sulphoxides is described. In this process, a pro-chiral sulphide is oxidised with an oxidising agent in the presence of a chiral titanium complex into the corresponding sulphoxide either as a single enantiomer or in enantiomerically enriched form.
Single enantiomers of omeprazole in neutral form are difficult to obtain in crystalline state and thus these compounds are most frequently obtained as non crystalline products. In for instance WO 92/08716 the neutral form of the R enantiomer of omeprazole is obtained as an amorphous solid and in WO 94/27988 both of the enantiomers of omeprazole - in their neutral forms - are obtained in the form of syrups or oils. In WO 94/27988 is also described the preparation of alkaline salts of the single enantiomers, which are obtainable as crystalline products. These can be purified by recrystallisation resulting in products of very high optical purity. Furthermore, optically pure salts of the S-enantiomer of omeprazole are stable towards racemization both in neutral pH and basic pH.
WO 98/28294 discloses S-omeprazole in neutral form that is in a solid state.
It would be desirable to perform the oxidation of pro-chiral sulphides yielding highly crystalline sulphoxide intermediates, thus making it possible to directly recrystallise the crude sulphoxides in its neutral form in order to increase the optical purity as well as to increase the chemical purity. The purified enantiomerically enriched sulphoxide intermediates could then be converted into the S- or R-enantiomer of omeprazole and thereafter optionally into pharmaceutically acceptable salts thereof. An advantage of such a process is that a requisite chemical and optical purification step would not involve the addition of an alkaline medium to a titanium containing reaction mixture, which process is associated with problems with the formation of inorganic titanium salts that are difficult to work with. A further advantage is if the titanium catalyzed reaction step occurrs earlier in the synthesis of the enantiomerically enriched compounds thereby reducing a possible risk of contamination of the final product by titanium salts.
The present invention relates to new crystalline sulphoxides which are stable enough to be directly recrystallised, the preparation of these sulphoxides and their use as intermediates in the synthesis of S- and R- enantiomer of omeprazole.
Detailed description of the invention
The present invention refers to new highly crystalline sulphoxides in enantiomerically enriched form which are chemically stable enough to be directly crystallised from an oxidation reaction mixture , the preparation of these sulphoxides and their use as intermediates in the synthesis of the S- and R- enantiomer of omeprazole and pharmaceutically acceptable salts thereof.
According to another aspect of the invention, the new synthetic intermediates are defined by formula I either as a single enantiomer or in enantiomerically enriched form:
wherein Het is
and X is a leaving group such as a halogen (F, Cl, Br, I), NO , N +or -OSO2R (R is CH3, CF3, p-toluene, m-chlorobenzene, p-chlorobenzene).
According to another aspect of the invention the leaving group X is chloro or nitro as in the compounds of formula la, lb, Ic and Id:
The compounds la-Id, and their corresponding tautomers, exist either as a single enantiomer or in an enantiomerically enriched form. A further aspect of the invention is the preparation of compounds of formula I, which can be used as intermediates in the synthesis of the S- and R- enantiomer of omeprazole and pharmaceutically acceptable salts thereof. The preparation of the compounds of formula I may be carried out as described in EP 0773 940 B 1, and this is also illustrated in Scheme 1 below.
Scheme 1
wherein Het is
and X is a leaving group such as a halogen (F, Cl, Br, I), NO2, N2 +or -OSO2R (R is CH3, CF , p-toluene, m-chlorobenzene, p-chlorobenzene).
In this process, a pro-chiral sulphide such as II is oxidised in an organic solvent with an oxidising agent, e.g. cumene hydroperoxide, in the presence of a chiral titanium complex. The titanium complex suitable for catalysing the process of the invention is prepared from a chiral ligand and a titanium(IV) compound such as preferably a titanium(IV)alkoxide, and optionally in the presence of water. The chiral ligand used in the preparation of the titanium complex is for instance a chiral alcohol such as a chiral diol. The oxidation may be performed in the presence of a base, e.g. N,N-diisopropylethylamine.
The oxidation is carried out in an organic solvent. The solvent can be chosen with respect to suitable conditions from an industrial point of view as well as environmental aspects. Suitable organic solvents are for instance toluene, ethyl acetate, methyl ethyl ketone, methyl isobutyl ketone, diethyl carbonate, tert.butyl methyl ether, tetrahydrofurane, methylene chloride and the like. From an environmental point of view non-chlorinated solvents are preferred.
The oxidation is preferably carried out in an organic solvent at room temperature or just above room temperature, e.g. between 20-40°C. If the reaction time is varied a reaction temperature may be chosen below as well as above the preferred temperatures 20 - 40°C. A suitable temperature range is limited only depending on the decomposition of the compounds, and that the reaction time is dramatically shorter at room temperature than at -20°C since the sulphides of interest are oxidised very slowly at such a low temperature.
An oxidising agent suitable for this asymmetric oxidation may be a hydroperoxide, such as for example tert.-butylhydroperoxide or cumene hydroperoxide, preferably the latter. The titanium complex suitable for catalysing the process of the invention is prepared from a chiral ligand and a titanium(IV)compound such as preferably titanium(IV)alkoxide, and optionally in the presence of water. An especially preferred titanium(IN )alkoxide is titanium(ιN)isopropoxide or -propoxide. The amount of the chiral titanium complex is not critical. An amount of less than approximately 0.50 equivalents is preferred and especially preferred amount is 0.05-0.30 equivalents. Even very low amounts of complex, such as for instance 0.04 equivalents may be used in the processes according to the present invention with excellent result.
The titanium complex may also be prepared by reacting titanium tetrachloride with a chiral ligand in the presence of a base.
The chiral ligand used in the preparation of the titanium complex is preferably a chiral alcohol such as a chiral diol. The diol may be a branched or unbranched alkyl diol, or an aromatic diol. Preferred chiral diols are esters or tartaric acid, especially (+)-diethyl L- tartrate or (-)-diethyl D-tartrate are preferred.
The chiral titanium complex may be prepared in the presence of the pro-chiral sulphide or before the pro-chiral sulphide is added to the reaction vessel.
According to one aspect of the invention, the oxidation is carried out in the presence of a base. The base may be an inorganic or an organic base, such as for instance a hydrogen carbonate, an amide or an amine. Amine includes a guanidine or an amidine. Organic bases are preferred and especially suitable bases are amines, preferably triethylamine or N,N- diisopropylethylamine. The amount of base added to the reaction mixture is not critical but should be adjusted with respect to the reaction mixture.
The preparation of the chiral titanium complex is preferably performed in the presence of the pro-chiral sulphide. Other essential features in the preparation of the chiral titanium complex is that the preparation of the complex is performed during an elevated temperature and/or a prolonged time. With an elevated temperature is meant a temperature above room temperature, such as for instance 30 - 70°C, preferably 40 - 60°C. A prolonged preparation time is a period of time longer than approximately 20 minutes, preferably 1 - 5 hours. A suitable period of time for the preparation step depends on the preparation temperature and of the pro-chiral sulphide, optionally present during the preparation of the chiral titanium complex.
Yet a further aspect of the invention is the conversion of compounds of formula I into the S- and R- enantiomer of omeprazole and pharmaceutically acceptable salts thereof. Scheme 2 and Scheme 3 below describe synthetic routes for converting compound I into the S- enantiomer of omeprazole. The same routes can be applied to convert compund I into the R-enantiomer of omeprazole provided that the chirality of the chiral titanium complex used in the oxidising reaction step is changed to the opposite of that used for making the corresponding S-enantiomer. Scheme 2
In Scheme 2, the first step is performed as described above. The obtained sulphoxide I may be recrystallised in order to enhance chemical and optical purity. Finally, a substitution reaction with methoxide, e.g. sodium methoxide, yields the S-enantiomer of omeprazole, which may be converted to a pharmaceutically acceptable salt thereof.
Scheme 3
In Scheme 3, the first step is performed as described above. Nucleophilic substitution of the leaving group X with methoxide, e.g. sodium methoxide, is thereafter performed prior to or after reduction of the pyridine-N-oxide to pyridine. The compounds of the invention may exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.
The invention is illustrated by the following non-limiting examples.
Example 1. Synthesis of ιS)-2-rr(4-chloro-3.5-dimethyl-2-pyridinvDmethyllsulfinyn5- methoxy- IH-benzimidazole
1.2 g (3.6 mmol) of 2- { [(4-chloro-3,5-dimethyl-2-pyridinyl)methyl]thio}-5-methoxy- IH- benzimidazole was mixed with toluene (40 mL). The mixture was concentrated until half the volume was left. Water (38 mg, 2.1 mmol), (S,S)-diethyl tartrate (1.85 g, 9.0 mmol) and titanium tetraisopropoxide (1.0 g, 3.6 mmol) were added in the given order while
stirring. The mixture was then stirred at 50°C for an hour and then N,N-
diisopropylethylamine (0.46 g, 3.6 mmol) was added at room temperature. After 15 minutes cumene hydroperoxide (80% in cumene, 0.69 g, 3.6 mmol) was added dropwise and stirring was then continued for 2 h at room temperature. The optical purity of crude sulfoxide turned out to be 75 % ee as determined by chiral ΗPLC analysis of the solution. The mixture was washed with water and then evaporated. The product was purified by chromatography on silica gel using methanol/dichloromethane as eluent (gradient, 1-7 % MeOΗ) and this afforded 1.0 g of a crude product as a solid. Recrystallisation from hot acetonitrile gave 0.35 g of a white solid with an enantiomeric excess of 51%. Next, the mother liqueur from the filtration was concentrated and this material was then also recrystallised from acetonitrile to give 0.35 g of the title compound as a crystalline product with an enantiomeric excess of 92.5 %. 1 H NMR of the most enriched fraction (92.5 % ee) in chloroform-d ; 2.3 (s, 3H), 2.4 (s, 3H), 3.8 (s, 3H), 4.8 (AB-system, 2H), 7.0 (dd, IH), 7.0 (b, IH), 7.5 (b, IH), 8.2 (s, IH).
Example 2. Synthesis of f"S)-2-rr(4-nitro-3,5-dimethyl-2-pyridinyl methyllsulfinyll5- methoxy- IH-benzimidazole
In an analogous experiment as in Example 1 - starting from 1.2 g of (Sj-2-[[(4-nitro-3,5- dimethyl-2-pyridinyl)methyl]thio]5-methoxy- IH-benzimidazole - 1.0 g of the title compound as a crystalline product was obtained. The enantiomeric excess of this crude product was determined to be 48 % by chiral ΗPLC analysis.

Claims

Claims
1. A compound of formula I either as a single enantiomer or in an enantiomerically enriched form
wherein Het is
and X is a leaving group such as a halogen (F, Cl, Br, I), NO2, N2 +or OSO2R (R is CH3, CF3, p-toluene, m-chlorobenzene, p-chlorobenzene), and tautomers thereof.
2. 2-[[(4-ChloiO-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]5-methoxy-lH-benzimidazole either as a single enantiomer or in an enantiomerically enriched form, and the tautomer thereof.
3. 2-[[(4-Nitro-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]5-methoxy-lH-benzimidazole either as a single enantiomer or in an enantiomerically enriched form, and the tautomer thereof.
4. 2-[[(4-Chloro-3,5-dimethyl-l-oxidopyridin-2-yl)methyl]sulfinyl]-5-methoxy-lH- benzimidazole either as a single enantiomer or in an enantiomerically enriched form, and the tautomer thereof.
5. 2-[[(4-Nitro-3,5-dimethyl-l-oxidopyridin-2-yl)methyl]sulfinyl]-5-methoxy-lH- benzimidazole either as a single enantiomer or in an enantiomerically enriched form, and the tautomer thereof.
6. A process for enantioselective synthesis of a sulphoxide of formula I either as a single enantiomer or in an enantiomerically enriched form
wherein Ηet is
and X is a leaving group such as a halogen (F, Cl, Br, I), NO2, N2 +or OSO2R (R is CH3, CF3, p-toluene, m-chlorobenzene, p-chlorobenzene), characterized in that a pro-chiral sulphide of the formula II
π wherein Het is defined as above, i) is oxidised in an organic solvent with an oxidising agent and in the presence of a chiral titanium complex and a base, or ii) is oxidised in an organic solvent with an oxidising agent and in the presence of a chiral titanium complex, optionally in the presence of a base, wherein the titanium complex has been prepared in the presence of the pro-chiral sulphide, or iii) is oxidised in an organic solvent with an oxidising agent and in the presence of a chiral titanium complex, optionally in the presence of a base, wherein the titanium complex has been prepared during an elevated temperature and/or a prolonged preparation time, or iv) is oxidised in an organic solvent with an oxidising agent and in the presence of a chiral titanium complex, optionally in the presence of a base, wherein the titanium complex is prepared in the presence of the pro-chiral sulphide and during an elevated temperature and/or during a prolonged preparation time
7. A process for synthesizing S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)- methyljsulphinyl]- IH-benzimidazole using as starting material a compound according to Formula I, wherein the leaving group is replaced by methoxide, or alternatively the leaving group is replaced by methoxide prior to or after reduction of the oxidopyridine to pyridine.
8. S-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulphinyl]-lH- benzimidazole prepared by a process comprising a combination of steps from the process defined in claims 6 and 7.
9. A pharmaceutical preparation comprising the S-5-methoxy-2-[[(4-methoxy-3,5- dimethyl-2-ρyridinyl)-methyl]sulphinyl]-lH-benzimidazole and a pharmaceutically acceptable carrier or diluent characterized in that the S-5-methoxy-2-[[(4-methoxy-3,5- dimethyl-2-pyridinyl)-methyl]sulphinyl]-lH-benzimidazole is prepared by a process according to claims 6 and 7.
EP05711081A 2004-02-20 2005-02-17 New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation Expired - Lifetime EP1718636B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400410A SE0400410D0 (en) 2004-02-20 2004-02-20 New compounds
PCT/SE2005/000221 WO2005080374A1 (en) 2004-02-20 2005-02-17 New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation

Publications (2)

Publication Number Publication Date
EP1718636A1 true EP1718636A1 (en) 2006-11-08
EP1718636B1 EP1718636B1 (en) 2012-01-18

Family

ID=31989582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05711081A Expired - Lifetime EP1718636B1 (en) 2004-02-20 2005-02-17 New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation

Country Status (8)

Country Link
US (4) US20080255199A1 (en)
EP (1) EP1718636B1 (en)
JP (1) JP2007523160A (en)
AT (1) ATE541838T1 (en)
CA (1) CA2553877C (en)
ES (1) ES2378237T3 (en)
SE (1) SE0400410D0 (en)
WO (1) WO2005080374A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400410D0 (en) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2007088559A1 (en) * 2006-02-01 2007-08-09 Jubilant Organosys Limited Process for producing substituted sulphoxides
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
WO2009066321A2 (en) * 2007-10-03 2009-05-28 Ipca Laboratories Limited Process for optically active sulfoxide compounds
WO2010011856A2 (en) * 2008-07-23 2010-01-28 Board Of Regents Of The University Of Nebraska Stereospecificity of methylsulfinyl reduction
CN108484578B (en) * 2018-04-09 2019-03-26 珠海润都制药股份有限公司 A kind of method of esomeprazole impurity preparation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
ES2026761A6 (en) 1990-10-31 1992-05-01 Genesis Para La Investigacion A process for the preparation of omeprazol.
DE4035455A1 (en) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE504459C2 (en) * 1994-07-15 1997-02-17 Astra Ab Process for the preparation of substituted sulfoxides
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (en) * 1996-12-20 1999-06-14 Astra Ab New Crystal Modifications
WO1998040377A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
WO1998040378A1 (en) 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
US6303787B1 (en) * 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
ES2166269B1 (en) 1999-07-14 2003-04-01 Sint Quimica Sa NEW PROCEDURE FOR OBTAINING DERIVATIVES OF 2- (2-PIRIDINILMETILSULFINIL) -1H-BENZIMIDAZOL.
PT102361B (en) 1999-09-22 2002-07-31 Herbex Produtos Quimicos Lda METHOD OF OBLIGATION OF ARILETERS AND TIOETERS USING MICRO-WAVES RADIATION
WO2001083473A1 (en) * 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Process for producing optically active sulfoxide derivative
DE60131649T2 (en) * 2000-05-15 2008-10-30 Takeda Pharmaceutical Co. Ltd. PROCESS FOR PREPARING A CRYSTAL
AU2000258410A1 (en) 2000-07-28 2003-12-02 Herbex, Produtos Quimicos, Sa New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
ES2187248B1 (en) 2000-08-25 2004-01-16 Sint Quimica Sa NEW PROCEDURE FOR OBTAINING DERIVATIVES OF 2- (2-PIRIDINILMETILSULFINIL) -1H-BENZIMIDAZOL.
WO2003089408A2 (en) 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2005054228A1 (en) 2003-12-05 2005-06-16 Hetero Drugs Limited A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
SE0400410D0 (en) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005080374A1 *

Also Published As

Publication number Publication date
HK1098474A1 (en) 2007-07-20
US20080255199A1 (en) 2008-10-16
CA2553877A1 (en) 2005-09-01
US20070161682A1 (en) 2007-07-12
US20050187256A1 (en) 2005-08-25
JP2007523160A (en) 2007-08-16
SE0400410D0 (en) 2004-02-20
ATE541838T1 (en) 2012-02-15
CA2553877C (en) 2012-07-31
EP1718636B1 (en) 2012-01-18
US8697880B2 (en) 2014-04-15
US20090253911A1 (en) 2009-10-08
ES2378237T3 (en) 2012-04-10
WO2005080374A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
AU688074B2 (en) Process for synthesis of substituted sulphoxides
KR101522865B1 (en) Process for the preparation of form a of esomeprazole magnesium dihydrate
CA2450433C (en) Improved process for preparing benzimidazole-type compounds
US8697880B2 (en) Compounds useful for the synthesis of S- and R-omeprazole and a process for their preparation
JP4612542B2 (en) Process for the production of optically pure active compounds
AU2003269773A1 (en) Method for the synthesis of a benzimidazole compound
WO2010095144A2 (en) Process for the preparation of proton pump inhibitors
HK1098474B (en) New compounds useful for the synthesis of s-and r-omeprazole and a process for their preparation
US8198455B2 (en) Process for the preparation of dexlansoprazole
US20070225500A1 (en) Process for the Preparation of Pyridin-2-Ylmethylsulphinyl-1H-Benzimidazol Compounds
EP2342193B1 (en) Novel compounds for producing substituted sulfoxides, process for producing the same and use thereof
US20130030186A1 (en) Process for preparing sulphoxide compounds
HK1008331B (en) Process for synthesis of substituted sulphoxides
KR20070105018A (en) Method of Preparing Rabeprazole and Its Intermediate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098474

Country of ref document: HK

17Q First examination report despatched

Effective date: 20100211

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 541838

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120215

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005032256

Country of ref document: DE

Effective date: 20120322

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2378237

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120410

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120118

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120518

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120419

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120518

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 541838

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098474

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

26N No opposition filed

Effective date: 20121019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120217

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005032256

Country of ref document: DE

Effective date: 20121019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050217

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20160211

Year of fee payment: 12

Ref country code: ES

Payment date: 20160113

Year of fee payment: 12

Ref country code: DE

Payment date: 20160209

Year of fee payment: 12

Ref country code: IT

Payment date: 20160222

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20160211

Year of fee payment: 12

Ref country code: GB

Payment date: 20160217

Year of fee payment: 12

Ref country code: FR

Payment date: 20160108

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005032256

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170218

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170901

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170217

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170217

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170218